Argentina
| Artículos de revistas
Metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study
Fecha
2013-09Registro en:
Elia, Evelin Mariel; Quintana, Ramiro; Carrere, Carlos; Bazzano, María Victoria; Rey Valzacchi, Gastón ; et al.; Metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study; BioMed Central; Journal of Ovarian Research; 6; 1; 9-2013; 62-70; 62
1757-2215
CONICET Digital
CONICET
Autor
Elia, Evelin Mariel
Quintana, Ramiro
Carrere, Carlos
Bazzano, María Victoria
Rey Valzacchi, Gastón
Paz, Dante Agustin
Pustovrh, María Carolina
Resumen
Background: In assisted reproduction cycles, gonadotropins are administered to obtain a greater number of oocytes. A majority of patients do not have an adverse response; however, approximately 3-6% develop ovarian hyperstimulation syndrome (OHSS). Metformin reduces the risk of OHSS but little is known about the possible effects and mechanisms of action involved. Objective: To evaluate whether metformin attenuates some of the ovarian adverse effects caused by OHSS and to study the mechanisms involved. Material and methods: A rat OHSS model was used to investigate the effects of metformin administration. Ovarian histology and follicle counting were performed in ovarian sections stained with Masson trichrome. Vascular permeability was measured by the release of intravenously injected Evans Blue dye (EB). VEGF levels were measured by commercially immunosorbent assay kit. COX-2 protein expression was evaluated by western blot and NOS levels were analyses by immunohistochemistry. Results: Animals of the OHSS group showed similar physiopathology characteristics to the human syndrome: increased body weight, elevated progesterone and estradiol levels (P<0.001), increased number of corpora lutea (P<0.001), higher ovarian VEGF levels and vascular permeability (P<0.001 and P<0.01); and treatment with metformin prevented this effect (OHSS+M group; P<0.05). The vasoactive factors: COX-2 and NOS were increased in the ovaries of the OHSS group (P<0.05 and P<0.01) and metformin normalized their expression (P<0.05); suggesting that metformin has a role preventing the increased in vascular permeability caused by the syndrome. Conclusion: Metformin has a beneficial effect preventing OHSS by reducing the increase in: body weight, circulating progesterone and estradiol and vascular permeability. These effects of metformin are mediated by inhibiting the increased of the vasoactive molecules: VEGF, COX-2 and partially NOS. Molecules that are increased in OHSS and are responsible for a variety of the symptoms related to OHSS.